返回排名列表

Waters Corp (WAT)

被高估
HealthcareDiagnostics & ResearchUnited States

基本面

50

价格

$431.37

市值

$43.49B

第一部分 · 这家公司值多少

概览

Waters Corporation provides analytical workflow solutions in Asia, the Americas, and Europe. The company operates through two segments, Waters and TA. The company designs, manufactures, sells, and services liquid chromatography, as well as mass spectrometry (MS) technology systems and supports products, including chromatography columns, and other consumable products. It also designs, manufactures, sells, and services thermal analysis, rheometry, and calorimetry instruments for use in predicting the suitability and stability of fine chemicals, pharmaceuticals, water, polymers, metals, and viscous liquids for various industrial, consumer goods, and healthcare products, as well as for life science research; and develops and supplies software-based products that interface with its instruments, as well as other manufacturers' instruments. In addition, the company offers MS technology, which is used in drug discovery and development comprising clinical trial testing, the analysis of proteins in disease processes, nutritional safety analysis, and environmental testing. Its products are used by clinical, pharmaceutical, biochemical, industrial, nutritional safety, environmental, academic, and governmental customers working in research and development, quality assurance, and other laboratory applications. The company was founded in 1958 and is headquartered in Milford, Massachusetts.

No editorial profile for this company yet

Direct competitors

Who this company fights with for the same customers

No editorial profile for this company yet

No competitor list for this company yet.

资产负债表与流动性

营收

$4.64B

最近12个月(截至2026/7/4)

净利润

$166M

最近12个月(截至2026/7/4)

自由现金流

$540M

股东权益合计

$2.56B

负债合计

$2.52B

流动比率

1.86

利息覆盖率

2.21

债务/EBITDA

3.62

每股收益

营收与净利润

自由现金流

收入构成

历史财务表

利润率变化

债务变化

债务负担有多重

增长一览表

增长 — 营业收入

公允价值估算

一般情形被高估

公允价值

$312.84

当前价格

$431.37

安全边际

-37.9%

公允价值区间

$203.35 - $422.33

所用估值方法之间的离散区间,并非经过统计校准的置信区间。

估算方法

分析师目标价:$444.79
现金流折现法(DCF):$87.65
市盈率法(P/E):$103.45
格雷厄姆成长公式:$65.63
盈利能力价值(EPV):$24.06
合理市净率(P/B):数据不足,无法计算
股息折现模型(戈登模型):数据不足,无法计算
P/FFO(运营资金):数据不足,无法计算
周期中段收益:$258.21
市销率法(P/S):$186.33
分析师共识:买入 (20B / 11H / 0S)
最近财报超预期:+0.44%

估值指标

市盈率(P/E)

109.57

ROE

25.1%

市净率(P/B)

2.84

P/FCF

80.62

毛利率

59.3%

ROIC

1.2%

盈利能力雷达图

价值创造(经济护城河)

ROIC

1.2%

WACC

10.0%

ROIC − WACC

-8.8 pp

ROIC 低于资本成本:公司每投入一美元都在毁灭价值。

基本面分析标准

通过(18)

  • EPS shows upward trend
  • EPS CAGR 8.16%
  • Price CAGR 11.76%
  • Gross Margin 59.3%
  • P/B Ratio 2.84
  • Debt/Equity ratio
  • Operating Margin 7.1%
  • Positive Free Cash Flow
  • CapEx intensity
  • Current Ratio
  • Interest Coverage
  • Debt/EBITDA
  • Revenue Growth 5Y 6.0%
  • Analyst Consensus 65% Buy
  • Earnings Surprise avg 4.9%
  • Earnings Quality (OCF/NI) 1.02
  • Share Dilution 0.3%
  • Piotroski F-Score 5/9

未通过(9)

  • ROIC 1.2%
  • P/FCF 80.62
  • Return on Tangible Assets
  • Low reliance on intangibles
  • Price below Graham Number
  • DCF valuation (Overvalued)
  • ROE 1.9%
  • PEG Ratio 50.28
  • Net Margin Trend 20.3% vs 21.6%

不可用(1)

  • Dividend Payout NaN%

Piotroski F-评分

5/9

信号混杂:部分领域需关注

score
criteria

盈利质量

1.02

高质量:盈利有现金流支撑

股权稀释

0.3%

股份数量稳定

机构持股

公司治理

管理团队

姓名职位年龄
Dr. Udit Batra Ph.D.President, CEO & Director54
Mr. Amol ChaubalSenior VP & CFO48
Ms. Jianqing Y. BennettSenior Vice President of Waters Advanced Diagnostics Division55
Mr. Christos RossSenior Vice President of Global Operations-
Mr. Brook M. ColangeloSenior VP & Chief Information Officer47
Mr. Caspar TudorHead of Investor Relations-
Ms. Keeley A. Aleman J.D.Senior VP, General Counsel, Head of Global Human Resources & Corporate Secretary48
Ms. Kristen GarveySenior Vice President of Global Communications-
Dr. Daniel Rush Ph.D.Senior Vice President of Global Research & Strategy-
Mr. Allan JaenickeSenior Vice President of Transformation-

审计风险

8

董事会风险

5

薪酬风险

7

股东权利风险

4

第二部分 · 价格与买入时机

这一部分不判断公司是否值得拥有:它帮助你在基本面说服你之后,选择何时买入。包含:技术分析、潜力、历史回撤、Gamma 敞口。

文件

  • 年度报告(10-K)

    对公司业务、财务业绩和风险的年度概述。

    提交日期:2026-02-23

    查看文件
  • 季度报告(10-Q)

    最近三个月财务表现的最新情况。

    提交日期:2026-08-11

    查看文件
  • 临时报告(8-K)

    关于重大事件(如管理层变动或重要公告)的通知。

    提交日期:2026-08-21

    查看文件

via SEC EDGAR

损益历史

via SEC EDGAR

Latest News

Recent headlines for WAT, sourced from Markets Gazette.

No recent news for WAT.